Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK – Get Free Report) in a research note issued to investors on Friday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Up 4.6 %

Check-Cap stock opened at $2.24 on Friday. Check-Cap has a 1 year low of $1.39 and a 1 year high of $4.63. The company has a market cap of $13.09 million, a PE ratio of -0.74 and a beta of 0.45. The company’s 50-day moving average is $2.27 and its two-hundred day moving average is $2.45.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Articles

• Five stocks we like better than Check-Cap
• Using the MarketBeat Stock Split Calculator
• The Real Reason Michael Burry is Buying Physical Gold
• Election Stocks: How Elections Affect the Stock Market
• Investing in 5G Stocks: Still an Opportunity
• What Does Downgrade Mean in Investing?
• Cisco Systems Rebound is On: Double-Digit Upside to Come

Receive News & Ratings for Check-Cap Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Check-Cap and related companies with MarketBeat.com’s FREE daily email newsletter.